

Tom van Meerten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4481081/publications.pdf>

Version: 2024-02-01

47
papers

1,705
citations

516710

16
h-index

302126

39
g-index

47
all docs

47
docs citations

47
times ranked

2711
citing authors

#	ARTICLE	IF	CITATIONS
1	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. <i>Cancers</i> , 2022, 14, 299.	3.7	11
2	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. <i>Blood Advances</i> , 2022, 6, 1537-1546.	5.2	45
3	Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 36.	6.2	8
4	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	5.2	35
5	DSP107 combines inhibition of CD47/SIRP α axis with activation of 4-1BB to trigger anticancer immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 97.	8.6	12
6	Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. <i>HemaSphere</i> , 2022, 6, e0711.	2.7	7
7	CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. <i>Biomedicines</i> , 2022, 10, 1175.	3.2	16
8	Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7548-7548.	1.6	3
9	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	1.4	22
10	Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. <i>HemaSphere</i> , 2021, 5, e523.	2.7	15
11	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	2.5	88
12	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	7.4	498
13	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. <i>Blood Advances</i> , 2021, 5, 2958-2964.	5.2	11
14	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	2.5	47
15	CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. <i>Scientific Reports</i> , 2021, 11, 20499.	3.3	11
16	Radiotherapy Is an Excellent Bridging Strategy in Large B-Cell Lymphoma Patients Selected for CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2510-2510.	1.4	1
17	For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation. <i>Blood</i> , 2021, 138, 754-754.	1.4	0
18	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2-2.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. <i>Lancet Haematology</i> , 2020, 7, e479-e489.	4.6	14
20	Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. <i>Leukemia</i> , 2020, 34, 2536-2538.	7.2	15
21	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020, 4, e302.	2.7	10
22	WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062071989837.	2.5	12
23	Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. <i>British Journal of Haematology</i> , 2020, 190, 40-44.	2.5	15
24	WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. <i>Cancers</i> , 2019, 11, 1743.	3.7	12
25	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 1663-1671.	3.4	28
26	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. <i>Nature Communications</i> , 2019, 10, 533.	12.8	26
27	Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1600349.	0.7	4
28	Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. <i>European Radiology</i> , 2019, 29, 6018-6028.	4.5	6
29	Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6036.	4.1	13
30	Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7558-7558.	1.6	7
31	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT. <i>Blood</i> , 2019, 134, 701-701.	1.4	1
32	Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma. <i>Nuclear Medicine Communications</i> , 2018, 39, 572-578.	1.1	5
33	Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 905-907.	1.8	3
34	CD20-selective inhibition of CD47-SIRP1 α doesn't eat me-signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolmmunology</i> , 2018, 7, e1386361.	4.6	58
35	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2018, 10, 459.	3.7	16
36	Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. <i>PLoS ONE</i> , 2018, 13, e0193098.	2.5	20

#	ARTICLE	IF	CITATIONS
37	CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 2852-2852.	1.4	0
38	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. <i>Journal of Immunology</i> , 2016, 197, 4829-4837.	0.8	30
39	Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2015, 194, 911-920.	0.8	228
40	Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation. <i>Blood</i> , 2014, 124, 4799-4799.	1.4	13
41	Novel antibodies against follicular non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 231-256.	1.7	21
42	CD20-Targeted Therapy: The Next Generation of Antibodies. <i>Seminars in Hematology</i> , 2010, 47, 199-210.	3.4	85
43	Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 4027-4035.	7.0	217
44	Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer.. <i>Blood</i> , 2006, 108, 5488-5488.	1.4	0
45	Complement-Induced Cell Death by Rituximab Depends on CD20-Expression Level and Acts Complementary to Antibody-Dependent Cell-Mediated Cytotoxicity.. <i>Blood</i> , 2005, 106, 775-775.	1.4	0
46	A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5538-5538.	1.4	0
47	High, Stable and Homogenous CD20 Expression for Efficient Rituximab-Induced Elimination of CD20+ Alloreactive Donor T Cells in the Novel CD20/Rituximab ζ Suicide System.. <i>Blood</i> , 2004, 104, 1750-1750.	1.4	0